Skip to main content
Top
Published in: Cancer Causes & Control 5/2009

01-07-2009 | Original Paper

Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care

Authors: Maria Paula Curado, Lydia Voti, Ana Maria Sortino-Rachou

Published in: Cancer Causes & Control | Issue 5/2009

Login to get access

Abstract

Cancer registration data plays a major role in the design and monitoring of cancer control activities and policies, and population-based cancer registries (PBCR) are the main source of information. In developed countries, the healthcare infrastructure enables the registration of quality cancer data. In low and middle Income countries (LMIC), where health care facilities are limited or scarce, cancer registration data may be of low quality. The aim of this article is to demonstrate the value of cancer incidence data for LMIC, even when quality is questionable, as well as to attempt to interpret the messages that the quality indicators convey both for cancer registration and the healthcare system. The study of data submitted to the Cancer incidence in five continents, volume nine (CI5-IX) leads to the conclusion that when PBCR from LMIC cannot provide good quality data it may indicate a deficiency that goes above and beyond the registrar ability. The quality control indicators evaluated provide insight on local conditions for cancer diagnosis and care. Low data quality not only signals lack of collaboration among reporting sources and the inability of the registrar to perform quality abstracting, but also points to specific weaknesses of the cancer care system and can guide improvement goals and efforts.
Literature
2.
go back to reference Curado MP, Edwards B, Shin HR, Strom H, Ferlay J, Heanue M et al (2007) Cancer incidence in five continents—Volume IX. IARC 2007 November 28. Available from URL http://www-dep.iarc.fr Curado MP, Edwards B, Shin HR, Strom H, Ferlay J, Heanue M et al (2007) Cancer incidence in five continents—Volume IX. IARC 2007 November 28. Available from URL http://​www-dep.​iarc.​fr
6.
go back to reference Muir CS, Percy C (1991) Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Sci Publ 95:64–81 Muir CS, Percy C (1991) Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Sci Publ 95:64–81
7.
go back to reference Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5 version 2.0 2004. Available from URL http://www-dep.iarc.fr/ Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5 version 2.0 2004. Available from URL http://​www-dep.​iarc.​fr/​
8.
go back to reference Working Group of the International Association of Cancer Registries (2005) Guidelines on confidentiality for population-based cancer registration. Eur J Cancer Prev 144:309–327. doi:10.1097/00008469-200508000-00003 Working Group of the International Association of Cancer Registries (2005) Guidelines on confidentiality for population-based cancer registration. Eur J Cancer Prev 144:309–327. doi:10.​1097/​00008469-200508000-00003
Metadata
Title
Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care
Authors
Maria Paula Curado
Lydia Voti
Ana Maria Sortino-Rachou
Publication date
01-07-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9288-5

Other articles of this Issue 5/2009

Cancer Causes & Control 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine